Oncologists define luminal A as estrogen receptor (ER) > 1%, progesterone receptor (PR) ≥ 20%, breast cancer with negative human epidermal growth factor receptor-2 (HER2), and Ki-67 < 14% of clinical cases [4]. Here, ERBB2 is linked to breast carcinoma.